Hospital
Barnesville Hospital Association, INC.
Barnesville Hospital Association, INC. was paid $3.14M by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoBARNESVILLE HOSPITAL ASSOCIATION, INC.
BARNESVILLE, OH 43713
BARNESVILLE, OH 43713
33aNPI1235135450assigned 06/22/2005
33bProvider typeCritical Access Hospital
28Total paid$3.14M
24GClaims92,725
24DCodes billed97
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#21 of 26
Median peer was paid$5.33M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,542 | $145K | |
| 2019 | 5,806 | $158K | |
| 2020 | 5,119 | $190K | |
| 2021 | 6,480 | $217K | |
| 2022 | 7,291 | $255K | |
| 2023 | 35,147 | $996K | |
| 2024incomplete | 28,340 | $1.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 7,982 | 6,971 | $889K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 3,169 | 2,485 | $358K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 11% | 3,752 | 3,447 | $342K |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.8% | 739 | 500 | $214K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.7% | 1,792 | 1,389 | $210K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.6% | 524 | 411 | $146K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.0% | 522 | 426 | $127K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 803 | 501 | $84K |
| 80053 | Comprehensive metabolic panel | 2.5% | 6,980 | 5,581 | $80K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.5% | 914 | 889 | $80K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 1,369 | 307 | $66K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.7% | 963 | 827 | $53K |
85 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 146 | $50K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.4% | 1,309 | $45K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 11,515 | $40K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 1,802 | $35K |
| 80061 | Lipid panel | <1% | 2,025 | $28K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,727 | $27K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,584 | $24K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,195 | $22K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 356 | $18K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 335 | $18K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 748 | $17K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,356 | $17K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,292 | $17K |
| 82607 | <1% | 372 | $9K | |
| 73630 | <1% | 346 | $8K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 80 | $8K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 16 | $8K |
| 84439 | <1% | 308 | $6K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 271 | $6K |
| 97162 | <1% | 169 | $5K | |
| 97014 | <1% | 181 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 26 | $5K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 76 | $4K |
| 85610 | <1% | 711 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,776 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 27 | $4K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 118 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 18 | $3K |
| 81001 | <1% | 2,380 | $3K | |
| 82728 | <1% | 155 | $3K | |
| 83540 | <1% | 262 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,969 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 239 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 638 | $3K |
| 83735 | <1% | 1,264 | $3K | |
| 73610 | <1% | 123 | $3K | |
| 82248 | <1% | 458 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 855 | $2K |
| 82043 | <1% | 270 | $2K | |
| 80305 | <1% | 629 | $2K | |
| 85027 | <1% | 164 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,081 | $1K |
| 86140 | <1% | 92 | $1K | |
| 83880 | <1% | 585 | $1K | |
| 83690 | <1% | 1,069 | $1K | |
| 84484 | <1% | 1,284 | $1K | |
| 82570 | <1% | 80 | $949.08 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,144 | $853.09 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 774 | $807.30 |
| G0378 | Hospital observation service, per hour | <1% | 26 | $774.32 |
| 90715 | <1% | 35 | $700.29 | |
| 87077 | <1% | 236 | $659.48 | |
| 84481 | <1% | 31 | $654.20 | |
| 85652 | <1% | 130 | $602.26 | |
| 83605 | <1% | 946 | $569.18 | |
| 82746 | <1% | 70 | $546.77 | |
| 73030 | <1% | 15 | $523.67 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 72 | $503.87 |
| 85730 | <1% | 349 | $425.34 | |
| 87186 | <1% | 161 | $403.00 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 48 | $364.19 |
| 87040 | <1% | 344 | $303.35 | |
| 81025 | <1% | 608 | $273.83 | |
| 86618 | <1% | 12 | $179.91 | |
| 73130 | <1% | 31 | $147.51 | |
| 85379 | <1% | 149 | $109.20 | |
| 74022 | <1% | 14 | $100.70 | |
| 96376 | <1% | 33 | $78.88 | |
| 82077 | <1% | 110 | $69.83 | |
| 81003 | <1% | 55 | $43.71 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 853 | $36.48 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 249 | $15.01 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 708 | $9.90 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 42 | $6.65 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 71 | $0.14 |
| J2704 | Injection, propofol, 10 mg | 0% | 170 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 30 | $0.00 |
| 82150 | 0% | 29 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 35 | $0.00 |
| 82550 | 0% | 44 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 34 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 27 | $0.00 |
| 80076 | 0% | 13 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 16 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPHILLIPS, DAVID (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| ST John Sapulpa, INC. | Sapulpa, OK | $6.85M |
| Harrison Community Hospital, INC. | Cadiz, OH | $4.66M |
| Owasso Medical Facility, INC | Owasso, OK | $3.35M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.